Short Interest in Kamada Ltd. (NASDAQ:KMDA) Rises By 19.6%

Kamada Ltd. (NASDAQ:KMDA) was the target of a large increase in short interest in January. As of January 15th, there was short interest totaling 85,924 shares, an increase of 19.6% from the December 31st total of 71,840 shares. Currently, 0.2% of the company’s stock are short sold. Based on an average trading volume of 88,172 shares, the days-to-cover ratio is presently 1.0 days. Based on an average trading volume of 88,172 shares, the days-to-cover ratio is presently 1.0 days. Currently, 0.2% of the company’s stock are short sold.

Hedge Funds Weigh In On Kamada

A number of hedge funds and other institutional investors have recently bought and sold shares of KMDA. NewEdge Advisors LLC boosted its holdings in shares of Kamada by 4.2% in the third quarter. NewEdge Advisors LLC now owns 52,668 shares of the biotechnology company’s stock valued at $366,000 after acquiring an additional 2,125 shares in the last quarter. ARK Investment Management LLC lifted its position in Kamada by 1.2% in the third quarter. ARK Investment Management LLC now owns 256,217 shares of the biotechnology company’s stock valued at $1,779,000 after purchasing an additional 2,943 shares during the period. Two Sigma Investments LP boosted its holdings in Kamada by 4.3% in the 3rd quarter. Two Sigma Investments LP now owns 109,589 shares of the biotechnology company’s stock valued at $761,000 after purchasing an additional 4,504 shares in the last quarter. Huntleigh Advisors Inc. increased its position in Kamada by 3.9% during the 2nd quarter. Huntleigh Advisors Inc. now owns 135,776 shares of the biotechnology company’s stock worth $1,052,000 after purchasing an additional 5,151 shares during the period. Finally, Acadian Asset Management LLC raised its stake in shares of Kamada by 3.1% during the 2nd quarter. Acadian Asset Management LLC now owns 263,556 shares of the biotechnology company’s stock worth $2,053,000 after buying an additional 7,925 shares in the last quarter. 20.38% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

KMDA has been the subject of several recent analyst reports. Benchmark restated a “buy” rating on shares of Kamada in a research note on Thursday, January 8th. Wall Street Zen raised shares of Kamada from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 13th. HC Wainwright boosted their price target on shares of Kamada from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Kamada in a research note on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $14.00.

Kamada Stock Performance

Kamada stock traded down $0.09 during midday trading on Wednesday, hitting $8.10. 108,307 shares of the company’s stock were exchanged, compared to its average volume of 83,339. The stock has a market cap of $465.83 million, a price-to-earnings ratio of 22.50, a price-to-earnings-growth ratio of 0.70 and a beta of 0.94. Kamada has a 12-month low of $5.54 and a 12-month high of $9.15. The firm’s 50 day simple moving average is $7.48 and its 200 day simple moving average is $7.19.

Kamada (NASDAQ:KMDA) last announced its earnings results on Monday, November 10th. The biotechnology company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.01). Kamada had a return on equity of 7.89% and a net margin of 11.70%.The business had revenue of $47.01 million for the quarter, compared to analyst estimates of $154.21 million. On average, equities research analysts forecast that Kamada will post 0.23 EPS for the current fiscal year.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.